Attendee search 

Cerevel Therapeutics is a clinical-stage biopharmaceutical company that combines a deep understanding of the biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) receptor pharmacology to discover and develop new therapies.

We seek to transform the lives of people suffering from neuroscience diseases, including Parkinson’s disease, epilepsy and schizophrenia, through the development of novel therapies. We have built a highly experienced team of senior leaders and neuroscience drug developers who combine a nimble, results-driven biotech mindset with the proven expertise of pharmaceutical company drug discovery and development.

Bionus Biotechnology was established in 2018, with an angel investment of a Finnish Company Currently we have 15 team members, 10 full-time, and 100% master's degree or above. Bionus has in-depth cooperation with the Karolinska Institute , Tokyo Medical and Dental University and Machine Learning Tokyo, the core members of the team had the background of Nobel Prize laureate in 2018, Mr. Tasuku Honjo.

The team currently covers 2 major layouts (AI-assisted small molecule chemical drug screening and creation of new peptide vaccines), 6 types of diseases, 12 pipelines, of which the fastest is a First in class:
At present, we are looking forward to the project financing of the anti-tumor CTLA-4 novel peptide vaccine of 10 million yuan. The main usages is to complete the vaccine safety evaluation before the IND. The current anti-tumor CTLA-4 new peptide vaccine, preclinical trials have been nearly completed, and the effect is obvious. We are confident to make new technological innovations in tumor vaccines.

At FJS Biopharmaceutical Inc., we combine technological innovation with world class process excellence. These enable our customers to deliver their discoveries. In our extensive contract development services portfolio we use advanced technologies to quickly and efficiently deliver products such as monoclonal antibodies, complex proteins and recombinant proteins.

Changes in the global marketplace are quickly altering the demands on biopharmaceutical manufacturing facilities. we have changed to Continuous Manufacturing Processes design that is cost-effective, flexible and responsive to a diversified product line. Continuous manufacturing processes offers a number of advantages:
1. More agile and flexible, and can therefore respond more rapidly to changes in supply or demand.
2. Reducing or eliminating scale-up bottlenecks could also help to accelerate the path to market for breakthrough
pharmaceuticals.
3. More efficient, reliable and cost-effective than traditional batch methods, resulting in significant cost savings down the line.
4. Producing smaller environmental footprint and reduce the risk of product quality failures compared to batch systems.
5. Supports a systematic, scientific and risk-based approach to pharmaceutical development. Development of a robust
process relies on utilizing the acquired product and process understanding to identify sources of variation to product quality
and to design appropriate control strategies to address these risk areas.
6. provides an opportunity to utilize this enhanced product and process understanding to adopt advanced manufacturing
controls and to produce uniformly high-quality products with reduced waste resulting from the generation of out-of-
specification material.

We are a preferred global partner to the Biopharmaceutical, biotech and specialty ingredients markets. Our solutions improve life quality by preventing illness, enabling healthier lifestyles and supporting a safe environment.

A public pharmaceutical company

Pregene is a world-leading cell and gene therapy company. Pregene is committed to develop innovative gene and cell therapy technologies and create reliable products from continued innovation and R&D. And pregene can provide CDMO service.

High-content screening for AI-drug discovery

Kelun-Biotech Biopharmaceutical is a subsidiary of Kelun Pharmaceutical Group established in 2016

Looking for antibody and samall molecular out-license and in-license

A listed and famous Chinese pharmaceutical company and also the main profit center of CR pharmaceutical Group which is the 2nd largest pharmaceutical group in China. The company has rich experiences in collaboration with multinational companies such as Sanofi, Takeda, Roche, Bailey and Novo Nordisk and so on. We are looking forward to cooperating with partners whose assets could meet the unmet medical needs and whom desire to explore China market.